Drug Profile

Ori CAR 001

Alternative Names: Anti-GPC3 CAR-T cell therapy - OriginCell Therapeutics; G3-CAR-Ori2; Ori-C101; Ori-CAR-001; OriC101 - OriCell Therapeutics

Latest Information Update: 15 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OriginCell Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

07 Jun 2026 China's National Medical Products Administration (NMPA) approves a confirmatory Phase II clinical trial of Ori CAR 001 in patients with GPC3-positive advanced hepatocellular carcinoma (HCC)
07 Jun 2026 Efficacy data from the phase I/II BEACON trial in Liver cancer released by OriCell Therapeutics
02 Jun 2026 Efficacy, adverse events and pharmacodynamics data from a phase I BEACON trial in Liver cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com